ABOUT US

Dr. Garg has served as president and chief executive officer (CEO) for Altimmune since November 2018. He has more than three decades of experience in the biotechnology and pharmaceutical industries with a successful track record of building and leading private and publicly traded companies. Prior to joining Altimmune, he served as president and CEO of Neos Therapeutics (Nasdaq: NEOS), where he built a commercial-stage biopharmaceutical company and launched several branded therapeutic products. He served as president and CEO of Tranzyme Pharma, prior to Neos, where he progressed the company from a discovery-stage, emerging biotech to a Nasdaq-listed clinical-stage, drug development company. Prior to that, Dr. Garg served as CEO of Apex Bioscience, Inc. (acquired by Curacyte AGof Munich, Germany). He has held senior management positions at DNX Bio-Therapeutics, Inc., until its acquisition by Baxter Healthcare Corporation, Sunovion Pharmaceuticals, Inc. (formerly known as Sepracor Inc., now a subsidiary of Sumitomo Dainippon Pharma), and Bio-Response Inc. (acquired by Baxter Healthcare Corporation). Dr. Garg received his Ph.D. in Biochemistry in 1982 from the University of Adelaide, Australia, and his M.S. from IARI Nuclear Research Laboratory, New Delhi, India in 1978.

Will has served as chief financial officer for Altimmune since May 2018. He has extensive experience in audit, finance and accounting. Prior to joining Altimmune, Will consulted for several private and public companies where he provided guidance on a broad-range of accounting and tax-related needs both independently and as managing partner of Redmont Advisors CPAs. Prior to his consulting role, Will served as an audit manager at PwC and a division controller at Rheem, a multinational manufacturing company. Will is a Certified Professional Accountant. He earned his Bachelor of Science and Master of Business Administration from Auburn University at Montgomery.

Dr. Roberts has served as the chief scientific officer (CSO) for Altimmune since December 2012. He has two decades of experience managing scientific operations – leading small molecule and biologics research and drug development efforts with a focus on viral vectors and antiviral therapies. Prior to joining Altimmune, Dr. Roberts served as CSO for ImQuest BioSciences, Inc., where he led scientific operations and business development initiatives in cancer and antivirals. Dr. Roberts held multiple leadership positions at Wellstat Biologics Corporation from August 1996 to October 2010, including director of research and development where he was responsible for a portfolio of biologic candidates in oncology including a clinical-stage asset. He also led bioassay and upstream process development efforts, and the animal pharmacology program at Wellstat. Dr. Roberts completed a post-doctoral fellowship at the National Cancer Institute, Laboratory of Molecular Virology and received his Ph.D. from the Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences. He has numerous patents, peer-reviewed journal publications and has been invited to speak and chair numerous international conferences.

Dr. Harris is a seasoned medical professional with extensive experience in hepatology and gastroenterology and broad expertise in managing clinical trials from early stage development through successful Phase 3 trials. He has led multidisciplinary forums on drug development and clinical trial design at national and international scientific meetings, and fostered collaborations between professional medical societies and the FDA. Previously, he was co-founder and chief medical officer of Lyric Pharmaceuticals, helping raise a $21 million Series A round in 2014. He has also served as chief medical officer of Avaxia Biologics, interim chief medical officer of Tranzyme Pharma, and chief medical officer of Ocera Therapeutics. Dr. Harris was also chief medical officer and vice president of Clinical Affairs at Napo Pharmaceuticals where he authored the pivotal clinical study that led to the approval of crofelemer (Mytesi®), the first Phase 2/3 adaptive trial design resulting in a drug approval. Earlier in his career he held senior roles in global clinical development and medical affairs at Otsuka Pharmaceuticals and Abbott. He sits on the faculty of Georgetown University School of Medicine as an Adjunct Professor, where he directs a course on drug development under a grant from the NIH. Dr. Harris has been a consultant on third-world drug development for the Bill and Melinda Gates Foundation and a speaker at national and international forums on drug development. Dr. Harris has an M.D. from Harvard Medical School and an MS in Administrative Medicine and Population Health from the University of Wisconsin Medical School. His post-graduate training includes residencies at John Hopkins Hospital and the University of Pennsylvania, and a Gastroenterology and Hepatology Fellowship at the Yale University School of Medicine.

Dr. Georges has served as chief technology officer for Altimmune since March 2015. He has nearly two decades of experience in product formulation and manufacturing, preclinical and early-stage clinical development, with a focus on T cell and peptide-based vaccines. Prior to joining Altimmune, Dr. Georges co-founded Immune Targeting Systems (ITS) Limited and served as the chief technology officer from 2004 until its acquisition by Altimmune in March 2015. Prior to ITS, Dr. Georges served as the of head of immunology at SEDAC-Therapeutics from 1999 until 2003. He received his Ph.D. in Molecular Immunology from the Pasteur Institute. Dr. Georges has co-authored 20 publications and is the co-inventor of 13 patent families.

José has served as chief business officer to Altimmune since July of 2018. He has more than two decades of experience structuring, negotiating and completing complex and accretive transactions including joint ventures, partnerships, mergers, acquisitions, debt financings, licensing and restructurings in a broad range of industries. Prior to joining Altimmune, he served as chief business officer and head of animal health Americas at IDT Biologika Corporation. José worked at Emergent BioSolutions and its predecessor BioPort Corporation for over a decade, prior to IDT, where he held several positions of increasing responsibility. José served as general counsel at BioPort, East West Resources Corporation, BellSouth International (now AT&T), Luce Forward Hamilton & Scripps and Arent Fox. He earned his juris doctor and bachelor of arts, with distinction, from the University of Virginia.

Dr. Sayare was appointed to the company’s board of directors in April 2010 and served as chairman of the board since January 2018. Most recently, he served as chairman and chief executive officer of ImmunoGen, a publicly traded biotechnology company engaged in the research and development of antibody-based cancer therapeutics. During his tenure with ImmunoGen, Dr. Sayare was responsible for leading a successful IPO and raising over $300 million in venture capital and public equity financing for the company. Dr. Sayare also served as president of the 95%-owned ImmunoGen subsidiary, Apoptosis Technology, where he was responsible for managing operations for the organization. Prior to joining ImmunoGen, Dr. Sayare served as vice president, development at Xenogen, Inc., a biotechnology company specializing in monoclonal antibody-based diagnostic systems for cancer. In this role he oversaw all research and development, corporate development and investor relations responsibilities for the company. Dr. Sayare earned his Ph.D. in biochemistry from the Temple University School of Medicine and his undergraduate degree from Ursinus College.

Dr. Drutz was first elected to our board of directors in January 2010 and served as chairman of the board between October 2011 and December 2017. He is the president of Pacific Biopharma Associates, a biopharmaceutical consulting company that he founded in January 1999. Between 2008 and 2015, he served as director (March 2008-December 2015), chief executive officer (December 2011-June 2014), executive chairman (June 2014-December 2015) and chief medical officer (January 2012-December 2015) of DARA BioSciences, an oncology supportive care company located in Raleigh, NC, which was acquired by Midatech Pharma in December 2015. Dr. Drutz served previously as chairman of Tranzyme, Inc. (NASDAQ:TZYM, 2000-2010) acquired by Ocera Therapeutics (NASDAQ:OCRX); director of MethylGene, Inc. (TSX:MYG, 2000-2010) acquired by Mirati Therapeutics (NASDAQ:MRTX); and director of Gentris Corporation (2007-2014), acquired by Cancer Genetics (NASDAQ:CGIX). From 1999 to 2008 he was a general partner with Pacific Rim Ventures, a Tokyo-based international venture capital firm. He is a former member of the Science and Industry Advisory Committee (SIAC) of Genome Canada, which advises Genome Canada’s board of directors regarding genomics investments throughout Canada. Dr. Drutz’s management experience includes tenures as VP biological sciences and VP clinical research at Smith Kline & French Laboratories, VP clinical development at Daiichi Pharmaceutical Corporation, and CEO of Inspire Pharmaceuticals (1995-1998) and Sennes Drug Innovations (1994-1995). Earlier in his career, Dr. Drutz was professor of medicine and chief of the division of Infectious Diseases at the University of Texas Health Science Center, San Antonio, and prior to that appointment was assistant professor of medicine and chief of the division of Infectious Diseases at the University of California, San Francisco/San Francisco General Hospital. Dr. Drutz received his M.D. from the University of Louisville School of Medicine and postgraduate training in internal medicine and infectious diseases at Vanderbilt University School of Medicine, serving subsequently as a research medical officer (infectious diseases) in the U.S. Navy with the rank of Lieutenant Commander. He is certified by the American Board of Internal Medicine, a fellow of the American College of Physicians and the Infectious Diseases Society of America, a member of the American Society of Clinical Oncology and the American Society for Clinical Investigation, and the author of more than 200 peer-reviewed articles, book chapters and abstracts for presentation. We believe Dr. Drutz’s experience in biotechnology investment and service as a board member and qualifications as a physician qualify him to serve as a member of our board of directors.

Mr. Hodges was first elected to our board of directors in September 2003 and is currently serving as chair of our audit committee. He is managing partner of Redmont Capital, a private equity firm located in Birmingham, Alabama, which he joined at its inception in 1997. Redmont Capital is a co-founder of our company. Mr. Hodges’ investment strategy is focused on high growth small businesses within the health care, life science and technology sectors. He currently serves as a director for several of the firm’s portfolio companies. Mr. Hodges holds a Bachelor of Science in Business Administration from the Brock School of Business at Samford University. We believe Mr. Hodges’ experience as a board member, life science investor and co-founder qualifies him to serve as a member of our board of directors.

Dr. Schafer has over 35 years of leadership experience, having held senior positions in government and industry. He has been a member of the board of directors since July 2012. He held the position of deputy assistant to the Secretary of Defense for chemical and biological defense, overseeing the Department of Defense $1.0 billion program for vaccine, therapeutics, medical device and sensor development. He retired from the Air Force as the assistant surgeon general and he accrued extensive experience managing all aspects of large integrated health care delivery systems and managing government science and technology portfolios. His private sector startup experience in telemedicine and as former CEO and co-founder of TessArae LLC, a biotech medical device company. He recently held the position of chief medical officer and client executive for health at CACI International. He has been an independent consultant since 2002 and has served as advisory board member to a number of biotech and health related companies. Dr. Schafer earned his MD at the University of Iowa, medical boards in family practice and aerospace medicine, his MPH at the University of Texas, his MS at the Dwight D. Eisenhower School of National Security and Resource Strategy.

Wayne Pisano was elected to join the company’s board in August of 2018. Mr. Pisano joined the board of directors of Provention Bio, Inc., a biopharmaceutical company, in April of 2018, and has served on the board of directors of Immunovaccine Inc., a biopharmaceutical company, since October 2011, and Oncolytics, Inc., a biotechnology company, since May 2013. Mr. Pisano served as president and CEO of VaxInnate, a biotechnology company, from January 2012 until November 2016. Mr. Pisano joined Sanofi Pasteur in 1997 and was promoted to president and CEO in 2007, the position he successfully held until his retirement in 2011. He has a bachelor’s degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio. The board believes that Mr. Pisano’s depth of experience across the spectrum of commercial operations, public immunization policies and pipeline development make him a valuable member of the board of directors.

Mr. Gill has served as president and chief executive officer of PharmAthene since March 2015 and has been a member of the company’s board of directors since 2004. Mr. Gill was a co-founder of TetraLogic Pharmaceuticals Corporation and served as its president and chief executive officer from 2003 to 2013. Prior to co-founding TetraLogic Mr. Gill was executive vice president, chief operating officer and a director of 3-Dimensional Pharmaceuticals, a drug discovery and development company that was acquired by Johnson and Johnson during March 2003. Mr. Gill has previously held positions at SmithKline Beecham Corporation, now GlaxoSmithKline, where he served as a member of the research and development executive committee, chairman of the Research and Development Operating Committee, vice president research and development operations and finance, a founding member and partner of SR One Ltd., chief operating officer of SK&F Nova Pharmaceuticals and earlier in a variety of finance roles. Mr. Gill is a Certified Public Accountant and served in the United States Marine Corps.

Dr. Garg has served as president and chief executive officer (CEO) for Altimmune since November 2018. He has more than three decades of experience in the biotechnology and pharmaceutical industries with a successful track record of building and leading private and publicly traded companies. From 2013 to 2018, he served as president and CEO of Neos Therapeutics (Nasdaq: NEOS), where he built a commercial-stage biopharmaceutical company and launched several branded therapeutic products. Prior to NEOS, he served as president and CEO of Tranzyme Pharma, where he progressed the company from a discovery-stage, emerging biotech to a Nasdaq-listed clinical-stage, drug development company. Prior to that, Dr. Garg held senior management positions at Apex Bioscience, Inc. (acquired by Curacyte AGof Munich, Germany), DNX Bio-Therapeutics, Inc., until its acquisition by Baxter Healthcare Corporation, Sunovion Pharmaceuticals, Inc. (formerly known as Sepracor Inc., now a subsidiary of Sumitomo Dainippon Pharma), and Bio-Response Inc. (acquired by Baxter Healthcare Corporation). Dr. Garg received his Ph.D. in Biochemistry from the University of Adelaide, Australia, and his M.S. from IARI Nuclear Research Laboratory, New Delhi, India.